New antituberculosis drugs, regimens, and adjunct therapies: needs, advances, and future prospects

• Published in: The Lancet infectious diseases Vol. 14; no. 4; pp. 327 - 340
• Main Authors: Zumla, Alimuddin I, Gillespie, Stephen H, Hoelscher, Michael, Philips, Patrick P J, Cole, Stewart T, Abubakar, Ibrahim, McHugh, Timothy D, Schito, Marco, Maeurer, Markus, Nunn, Andrew J
• Format: Journal Article
• Language: English
• Published: London Elsevier Ltd 01.04.2014; Lancet Publishing Group; Elsevier Limited
• Subjects: Antiretroviral agents; Antitubercular Agents - adverse effects; Antitubercular Agents - therapeutic use; Bacterial diseases; Biological and medical sciences; Biomarkers; Clinical trials; Clinical Trials as Topic; Developing countries; Distribution costs; Drug Discovery; Drug dosages; Drug resistance; Drug Therapy, Combination; Drugs; Human bacterial diseases; Humans; Immunotherapy; Infectious Disease; Infectious diseases; International cooperation; Laboratory methods; LDCs; Medical sciences; Medication Adherence; Mortality; Public health; Research Design; Tuberculosis; Tuberculosis and atypical mycobacterial infections; Tuberculosis, Multidrug-Resistant - drug therapy; Tuberculosis, Pulmonary - drug therapy; Tuberculosis, Pulmonary - therapy; Infection; Human; Chemotherapy; Treatment; Tuberculosis; Bacteriosis; Antituberculous agent; Mycobacterial infection; Antibacterial agent; Therapeutic protocol

About 1·3 million people died of tuberculosis in 2012, despite availability of effective drug treatment. Barriers to improvements in outcomes include long treatment duration (resulting in poor patient adherence and loss of patients to follow-up), complex regimens that involve expensive and toxic dru...